The expanded mbDNA portfolio delivers enhanced stability, reduced immunogenicity, and broad compatibility with gene insertion and expression technologies
Relmada expects to initiate its Phase 3 program in the first half of 2026
Venus Remedies now has 29 active product approvals in Vietnam alone
The FDA setback highlights ongoing tensions between patient needs, regulatory processes, and the use of real-world evidence in evaluating treatments for rare diseases
Poviztra is a second brand of Wegovy
The approval granted with zero supplementation requests is an important milestone in Glenmark’s respiratory pipeline
The said inspection concluded with Zero Form 483 observation
Syngene International has reported total income of Rs. 926 crore during the period ended September 30, 2025
Sumatriptan injection is indicated in adults for the acute treatment of migraine
Adjusted EBITDA increased by 12.3 per cent to $531 million, up from $516 million in the same period last year
Subscribe To Our Newsletter & Stay Updated
